FASLG and cryopyrin-associated periodic syndrome: Given the results from that review it was noted that rituximab could play a role in treatment of aPL positive patients and those with refractory CAPS, but its effectiveness could not be isolated to rituximab alone since patients received combined therapy with AC, CS, PE, and/or IVIG.